Tuesday, July 1st, 2025
Stock Profile: 9688.HK

Zai Lab Limited (9688.HK)

Market: HKEX | Currency: HKD

Address: Jinchuang Plaza

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK Show more




📈 Zai Lab Limited Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2022 - $10.000000 - 2022-03-30 - Stock split
Total Amount for 2022: $10.000000


📅 Earnings & EPS History for Zai Lab Limited


No earnings history available for this symbol.





📰 Related News & Research


No related articles found for "zai lab".